COGNITION THERAPEUTICS INC
جودة البيانات: 83%
CGTX
NASDAQ
Manufacturing
Chemicals
KWD 1.05
▲
KWD 0.07
(7.16%)
6 months return
—
Momentum
Neutral
ROE
-107.84%
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-107.84%
أقل من متوسط القطاع (-54.68%)
ROIC-171.65%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
N/A
Current Ratio6.44
Interest CoverageN/A
التقييم
PE (TTM|NTM)
-3.30 | -3.02
أقل من متوسط القطاع (-1.50)
P/B Ratio2.12
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Negative free cash flow of -24.59 M
Price History
الاتجاهات المالية
السعر المستهدف للمحللين
4 محللين
Buy
+234.9%
upside to target
الحالي
KWD 1.05
Consensus Target
KWD 3.50
KWD 3.00
أدنى
KWD 4.00
أعلى
التوقعات
مكرر الربحية المستقبلي
-3.02
ربحية السهم المستقبلية
-KWD 0.30
الإيرادات المقدّرة
0.0
مفاجآت الأرباح
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -KWD 0.07
·
Rev Est: 0.0
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -KWD 0.14 | -KWD 0.11 | -KWD 0.06 | -KWD 0.02 | — | — |
| Estimate | -KWD 0.12 | -KWD 0.11 | -KWD 0.09 | -KWD 0.08 | -KWD 0.07 | -KWD 0.07 |
| المفاجأة | -21.74% | -4.76% | +33.33% | +74.19% | — | — |
Growth
Rev 5Y: N/A · Earnings 1Y: N/A
Growth
Rev 5Y: N/A · Earnings 1Y: N/A| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
Profitability
ROE: -107.84% · Net Margin: N/A
Profitability
ROE: -107.84% · Net Margin: N/A| Revenue (TTM) | N/A | Net Income (TTM) | -23.49 M |
| ROE | -107.84% | ROA | -74.54% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -24.59 M |
| ROIC | -171.65% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 6.44
Safety
D/E: N/A · Current: 6.44| Debt / Equity | N/A | Current Ratio | 6.44 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 36.23 M | Tangible Book Value | 36.53 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -3.30 · EV/EBITDA: N/A
Valuation
P/E: -3.30 · EV/EBITDA: N/A| P/E Ratio | -3.30 | Forward P/E | -3.02 |
| P/B Ratio | 2.12 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -31.77% | ||
| Market Cap | 77.42 M | Enterprise Value | 38.08 M |
Per Share
EPS: -0.32 · FCF/Share: -0.28
Per Share
EPS: -0.32 · FCF/Share: -0.28| EPS (Diluted TTM) | -0.32 | Revenue / Share | N/A |
| FCF / Share | -0.28 | OCF / Share | -0.28 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 104.70% · CapEx/Rev: N/A
Efficiency
FCF Conv: 104.70% · CapEx/Rev: N/A| CapEx / Revenue | N/A | FCF Conversion | 104.70% |
| SBC-Adj. FCF | -27.22 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -23.49 M | -33.97 M | -25.79 M | -21.40 M | -11.72 M |
| EPS (Diluted) | -0.32 | -0.86 | -0.86 | -0.91 | -3.13 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -47.80 M | -53.97 M | -50.72 M | -43.55 M | -28.60 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 37.19 M | 41.68 M | 37.20 M | 30.32 M | 18.57 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 36,000.0 | 107,000.0 | 96,000.0 | 83,000.0 | 93,000.0 |
| Interest Expense | — | — | -27,000.0 | -28,000.0 | 895,000.0 |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 48.39 M | 30.23 M | 35.16 M | 50.43 M | 59.14 M |
| Total Liabilities | 14.12 M | 11.48 M | 10.69 M | 10.18 M | 7.86 M |
| Shareholders' Equity | 34.27 M | 18.75 M | 24.47 M | 40.25 M | 51.27 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 36.81 M | 25.01 M | 29.92 M | 41.56 M | 54.72 M |
| Current Assets | 47.99 M | 29.56 M | 34.22 M | 47.65 M | 58.99 M |
| Current Liabilities | 13.92 M | 11.14 M | 10.17 M | 7.80 M | 7.86 M |
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1605 نظير)
مقارنة بشركات مشابهة في Manufacturing
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1605 نظير) مقارنة بشركات مشابهة في Manufacturing| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -3.3 | -1.5 |
| P/B | 2.1 | 1.6 |
| ROE % | -107.8 | -54.7 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.7 |
| D/E | — | 0.3 |
{"event":"ticker_viewed","properties":{"ticker":"CGTX","listing_kind":"stock","pathname":"/stocks/cgtx","exchange":"NASDAQ","country":"US"}}